Anti-Obesity Therapeutics Market by Treatment Type, End-use

Description

List of Tables

[180 Pages Report] The Anti-Obesity Therapeutics Market size was estimated at USD 9.98 billion in 2023 and expected to reach USD 10.81 billion in 2024, at a CAGR 8.44% to reach USD 17.60 billion by 2030.

Global Anti-Obesity Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 9.98 billion
Estimated Year [2024]	USD 10.81 billion
Forecast Year [2030]	USD 17.60 billion
CAGR (%)	8.44%

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Obesity Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Obesity Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Type
- Medications
  - Bupropion-naltrexone
  - Liraglutide
  - Orlistat
  - Phentermine-topiramate
  - Semaglutide
- Treatments
  - Adjustable Gastric Banding
  - Endoscopic Sleeve Gastroplasty
  - Gastric Bypass Surgery
End-use
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-Obesity Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Obesity Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Anti-Obesity Therapeutics Market?

4. What is the market share of the leading vendors in the Anti-Obesity Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Anti-Obesity Therapeutics Market?

Product Code: MRR-EC2E133E33FA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Anti-Obesity Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing incidences of obesity and related disorder
  - 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
  - 5.1.1.3. Introduction of novel anti-obesity drugs
- 5.1.2. Restraints
  - 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing clinical trials and research & development activities
  - 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
- 5.1.4. Challenges
  - 5.1.4.1. Limited of knowledge regarding weight management
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Anti-Obesity Therapeutics Market, by Treatment Type

6.1. Introduction
6.2. Medications
- 6.3.1. Bupropion-naltrexone
- 6.3.2. Liraglutide
- 6.3.3. Orlistat
- 6.3.4. Phentermine-topiramate
- 6.3.5. Semaglutide
6.3. Treatments
- 6.4.1. Adjustable Gastric Banding
- 6.4.2. Endoscopic Sleeve Gastroplasty
- 6.4.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by End-use

7.1. Introduction
7.2. Ambulatory Surgical Centers
7.3. Hospitals
7.4. Specialty Clinics

8. Americas Anti-Obesity Therapeutics Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Anti-Obesity Therapeutics Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. Boehringer Ingelheim International GmbH
- 12.1.2. Bristol-Myers Squibb Company
- 12.1.3. Currax Pharmaceuticals LLC
- 12.1.4. Eisai Co., Ltd.
- 12.1.5. Eli Lilly and Company
- 12.1.6. F. Hoffmann-La Roche Ltd.
- 12.1.7. GlaxoSmithKline PLC
- 12.1.8. Merck & Co., Inc.
- 12.1.9. Norgine B.V.
- 12.1.10. Novartis AG
- 12.1.11. Novo Nordisk A/S
- 12.1.12. Pfizer Inc.
- 12.1.13. Rhythm Pharmaceuticals, Inc.
- 12.1.14. SHIONOGI & Co., Ltd.
- 12.1.15. Takeda Pharmaceutical Company Limited
- 12.1.16. Vivus LLC
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing